Navigation Links
BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
Date:4/21/2009

NOVATO, Calif., April 21 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the initiation of a Phase 1/2 clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. The company expects to report initial results in the first half of 2010.

"We plan to leverage our clinical, manufacturing and regulatory expertise to bring a new therapeutic option to the significant number of untreated Morquio patients around the world," said Henry Fuchs, M.D., Chief Medical Officer of BioMarin. "GALNS has been shown in mice to reach important tissues including cartilage and different zones of the bone such as bone marrow, calcified bone and importantly, the growth plate. Our experiments have also shown that GALNS is taken up into human Morquio chondrocytes in vitro and reaches the lysosome to clear keratan sulfate."

Chris Hendriksz, M.D., Consultant in Metabolic Disorders, Birmingham Children's Hospital, added, "This is a very exciting announcement for our patients who have been waiting so long for a potential therapy. Hope of a therapeutic is now within reach for these patients, and Birmingham Children's Hospital is very honoured to be part of this exciting development."

The Phase 1/2 study is designed as an open-label, within-patient dose escalation trial in approximately 20 patients followed by a treatment continuation phase. All patients to be enrolled in the study have already been identified. During the dose escalation phase of the study, subjects will receive weekly intravenous infusions of BMN-110 in three consecutive 12-week dosing intervals. The objectives of the Phase 1/2 study will be to evaluate safety, pharmacokinetics, pharmacodynamics and
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
2. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
3. BioMarin Announces FDA Approval for Kuvan
4. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
5. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
6. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
7. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
10. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), ... company, announced its financial results for the second quarter ended ... , Total revenues of $6.5 million in the second ... quarter in 2013 , Total revenues of $13.3 million ... of 78% over the same period in 2013 , ...
(Date:7/24/2014)... ANGELES , July 24, 2014 Many new ... they can do to ensure that their practice will be ... purchase the basic supplies they use the most can make ... and many dentists have recently discovered that purchasing discount ... loss. According to successful dentists across ...
(Date:7/24/2014)... N.C. , July 24, 2014 ... has signed an Agreement with Kineticos, a ... consulting company. Kineticos will support LSI Medience in ... sepsis management, to demonstrate utility in clinical trials. ... shown potential utility in diagnosis of sepsis, prognosis ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Dental Supplies Online is Key to Dental Success...Really! 2LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
... 28, 2011  A 67-year-old man with Alzheimer,s disease is ... outside in near-freezing temperatures thanks to the quick action of ... wearable locator device. Robert Campbell was recovered ... He was located on Victory Boulevard, more than a mile ...
... LOS ANGELES, Feb. 28, 2011 InstaCare Corp. (OTC ... provider of direct to patient diabetes programs, a leading ... chronically ill, and a leading developer of revolutionary cell ... on Thursday, February 24, 2011, the Company filed a ...
Cached Medicine Technology:Staten Island Man Now Safe at Home Thanks to EmSeeQ® Locator Device 2Staten Island Man Now Safe at Home Thanks to EmSeeQ® Locator Device 3InstaCare Files Full Utility Patent for MD@Hand & MD@Work Technologies 2InstaCare Files Full Utility Patent for MD@Hand & MD@Work Technologies 3
(Date:7/25/2014)... Silver®Care , for the first time in the United ... kill oral bacteria and airborne bacteria from the bathroom that ... the most common and important device in the prevention of ... to constant contamination by bacteria found in the mouth and ... mouth than anywhere else in the human body, and some ...
(Date:7/24/2014)... a renowned wedding dress manufacturer and retailer, has recently ... . According to the company’s marketing specialist, all these ... prices, up to 59% off. The special offer will ... Most of the casual party dresses provided by iFitDress.com ... for special designs, delicate craftsmanship and affordable rates. Now, ...
(Date:7/24/2014)... [Brown University] The U.S. Preventive Services Task ... for people at high risk for cancer, but ... patients will have positive results on the screening ... testing. Many policymakers have expressed concern that this ... needlessly upset. A new study of National Lung ...
(Date:7/24/2014)... The Traffic and Leads Training Academy ... help users generate traffic and leads has just been ... throughout the internet marketing community. The excitement surrounding the ... Hendricks prompting a comprehensive review of the course. ... marketing will tell you, it can be quite challenging ...
(Date:7/24/2014)... Triangle Park, NC (PRWEB) July 24, 2014 ... elderly, ethnic minorities, and low-income households are disproportionately ... and public food safety net in the United ... International. , Under Section 743 of the Consolidated ... U.S. Department of Agriculture's Food and Nutrition Service ...
Breaking Medicine News(10 mins):Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Informed consent: False positives not a worry in lung cancer study 2Health News:Informed consent: False positives not a worry in lung cancer study 3Health News:Traffic And Leads Training Academy - Review Examining Jeff Johnson’s New IM Course Released 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 3
... Accompanies Manuscript in March IssueTAMPA, Fla., March 2 ... peginterferon alfa-2a and ribavirin in patients with chronic ... was published in the March issue of ... Gastroenterological Association Institute (AGA Institute). The study showed ...
... 2 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: ... announced that the Company has amended the maturity ... with Valens U.S. (formerly Laurus Master Funds). , ... to a near-term extension of this facility, originally ...
... 2 Cardiac Science Corporation (Nasdaq: CSCX ... rehabilitation, and informatics products, announced today that it will ... March 12, 2009 after the market close. The Company ... for 4:30 p.m. Eastern Time. During the call, ...
... APA,s Psychologically Healthy Workplace Awards, Ten Honored for ... of the economy can be felt across all ... during tough economic times reap rewards for employer ... (APA) at its Psychologically Healthy Workplace Awards ceremony ...
... uninsured and underinsured is destabilizing state,s health care safety net. Health ... , ... Detroit, Michigan (PRWEB) March 2, 2009 -- ... and destabilizing the state,s health care delivery system. More than one ...
... Drinking one glass of wine a day may lower ... a new study by the Kaiser Permanente Division of Research ... is a precursor to esophageal cancer, the nation,s fastest growing ... the last 30 years. , Barrett,s Esophagus affects 5 ...
Cached Medicine News:Health News:Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology 2Health News:Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology 3Health News:Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology 4Health News:Bioniche Revolving Credit Facility Maturity Date Amended 2Health News:Cardiac Science Schedules Fourth Quarter Earnings Release and Announces Conference Call 2Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 2Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 3Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 4Health News:Cover The Uninsured Week, March 22 - 28 in Michigan 2Health News:Cover The Uninsured Week, March 22 - 28 in Michigan 3Health News:Cover The Uninsured Week, March 22 - 28 in Michigan 4Health News:Drinking wine lowers risk of Barrett's esophagus, precursor to nation's fastest growing cancer 2Health News:Drinking wine lowers risk of Barrett's esophagus, precursor to nation's fastest growing cancer 3
Provides 30% more illumination, high light output for true tissue. Wide-angle viewing lens, sealed system for pneumatic otoscopy....
... The Shandon Cryotome FE and FSE are ... Thermo Electron. The microtome is outside of ... cleaning, as well as faster temperature adjustment. ... operation. Complete temperature controls on the main ...
A standard, durable and reliable indirect....
Designed to retain the desired curve during oral intubation....
Medicine Products: